Results 11 to 20 of about 487 (135)

VNAR: shark single-domain antibodies for the new era of medical biotechnology [PDF]

Frontiers in Immunology
Shark-derived single-domain antibodies, known as VNARs, represent unique and advanced tools in medical biotechnology. Recognized for their small size, simple structure, and exceptional stability, VNARs can access cryptic epitopes that are inaccessible to
Richard A. Olivares-Olivares, Richard A. Olivares-Olivares, Angélica R. Bravo, Angélica R. Bravo, Carlos Garrido-Soto, Carlos Garrido-Soto, Jonatan J. Carvajal, Jonatan J. Carvajal, Augusto Manubens, Mariella Rivas, Mariella Rivas, Carlos Bustamente, Angello Retamal-Díaz, Angello Retamal-Díaz, Angello Retamal-Díaz, Alexis M. Kalergis, Alexis M. Kalergis, Margarita K. Lay, Margarita K. Lay, Margarita K. Lay   +19 more
doaj   +5 more sources

Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy [PDF]

Frontiers in Pharmacology, 2023
Aberrant activity of the cysteine protease Cathepsin S (CTSS) has been implicated across a wide range of pathologies. Notably in cancer, CTSS has been shown to promote tumour progression, primarily through facilitating invasion and migration of tumour ...
P. Smyth, L. Ferguson, J. F. Burrows, R. E. Burden, S. R. Tracey, Ú. M. Herron, M. Kovaleva, R. Williams, A. J. Porter, A. J. Porter, D. B. Longley, C. J. Barelle, C. J. Scott   +12 more
doaj   +6 more sources

Development and application of a VNAR-based detection nanobody for avian influenza virus H9N2 [PDF]

Frontiers in Immunology
The H9N2 subtype avian influenza virus, as a mutant strain of low-pathogenic avian influenza (LPAI), has augmented its transmission ability and pathogenicity via genetic evolution.
Hongzhou Ye, Qingqing Dong, Min Qian, Yanwen Guo, Yi Chen, Wenyuan Liu, Lili Liu, Zhengbing Lyu, Chen Yuan, Xiaofeng Jiang   +9 more
doaj   +3 more sources

A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy [PDF]

Acta Pharmaceutica Sinica B
TROP-2, a tumor-associated antigen, has been implicated in the progression of various epithelial tumors. Due to its favorable expression profile, TROP-2 has emerged as a promising target for antibody-drug conjugates (ADCs) based anti-tumor therapies. Although ADCs have shown efficacy in cancer treatment, their application in solid tumors is hindered by
Ming-Wei Wang, Qiang Wang, Zhicheng Zuo   +2 more
exaly   +4 more sources

A Single-Domain VNAR Nanobody Binds with High-Affinity and Selectivity to the Heparin Pentasaccharide Fondaparinux [PDF]

International Journal of Molecular Sciences
Glycosaminoglycans (GAGs) are key ligands for proteins involved in physiological and pathological processes. Specific GAG-binding patterns are rarely identified, with the heparin pentasaccharide as an Antithrombin-III ligand being the best characterized.
Martha Gschwandtner, Rupert Derler, Elisa Talker, Christina Trojacher, Nina Gubensäk, Walter Becker, Tanja Gerlza, Zangger Klaus, Pawel Stocki, Frank S. Walsh, Julia Lynn Rutkowski, Andreas Kungl   +11 more
exaly   +4 more sources

Identification of nurse shark VNAR single‐domain antibodies targeting the spike S2 subunit of SARS‐CoV‐2 [PDF]

The FASEB Journal, Volume 37, Issue 6, June 2023., 2023
Shark VNAR nanobodies targeting the S2 subunit of SARS‐CoV‐2 spike protein were identified from a naïve nurse shark VNAR phage display library by phage panning. The S2A9 VNAR showed the best neutralization activity against the original pseudotyped virus and was further characterized.
Jesse Buffington, Zhijian Duan, Hyung Joon Kwon, Jessica Hong, Dan Li, Mingqian Feng, Hang Xie, Mitchell Ho   +7 more
wiley   +2 more sources

Novel Approach for Obtaining Variable Domain of New Antigen Receptor with Different Physicochemical Properties from Japanese Topeshark (Hemitriakis japanica) [PDF]

Marine Drugs, 2023
Diverse candidate antibodies are needed to successfully identify therapeutic and diagnostic applications. The variable domain of IgNAR (VNAR), a shark single-domain antibody, has attracted attention owing to its favorable physicochemical properties.
Tomofumi Nakada-Masuta, Hiroyuki Takeda, Kazuhisa Uchida   +2 more
doaj   +2 more sources

Theranostic vNAR-Based Immunoconjugates Achieve Selective Intracellular Cisplatin Delivery in Embedded 3D HER2-Positive Breast Cancer In Vitro Model [PDF]

Pharmaceuticals
Background/Objectives: Precise intracellular delivery of chemotherapeutics remains a major challenge in HER2-positive breast cancer, where intratumoral heterogeneity and limited tissue penetration constrain efficacy.
Andrea C. Alfonseca-Ladrón de Guevara, Alejandro Manzanares-Guzmán, Jessica A. Badillo-Mata, Mirna Burciaga-Flores, Pavel H. Lugo-Fabres, Tanya A. Camacho-Villegas   +5 more
doaj   +2 more sources

First pan-specific vNAR against human TGF-β as a potential therapeutic application: in silico modeling assessment [PDF]

Scientific Reports, 2023
Immunotherapies based on antibody fragments have been developed and applied to human diseases, describing novel antibody formats. The vNAR domains have a potential therapeutic use related to their unique properties.
Mirna Burciaga-Flores, Ana Laura Márquez-Aguirre, Salvador Dueñas, Jahaziel Gasperin-Bulbarela, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas   +5 more
doaj   +2 more sources

Isolation and Characterization of Targeting-HBsAg VNAR Single Domain Antibodies from Whitespotted Bamboo Sharks (Chiloscyllium plagiosum) [PDF]

Marine Drugs, 2023
Immunoglobulin new antigen receptor (IgNAR) is a naturally occurring antibody that consists of only two heavy chains with two independent variable domains.
Xierui Jiang, Shan Sun, Zengpeng Li, Mingliang Chen   +3 more
doaj   +2 more sources